{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-120557","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.063313+00:00","generated_at":"2026-06-07T22:16:45.352662+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entrada completes first two cohorts in Phase 1 for ENTR-601-44; US clinical hold remains","bullets":["Completed dosing of first and second cohorts in Phase 1 trial ENTR-601-44-101 in the UK.","Data from Phase 1 trial expected in second half of 2024.","FDA clinical hold on IND remains in effect; FDA declined to lift hold despite additional data.","Company plans global development for exon 44 skipping amenable DMD patients.","Cash runway expected through 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-120557","json":"https://secwatch.observer/filing/0001104659-23-120557.json","markdown":"https://secwatch.observer/filing/0001104659-23-120557.md","text":"https://secwatch.observer/filing/0001104659-23-120557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923120557/0001104659-23-120557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923120557/tm2331388d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:16:45.352662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}